MIRXES-B:早期筛查蓝海市场的领航者,股价已翻倍!

新浪财经
Nov 14

在精准医疗投资热潮席卷全球的2024年, MIRXES-B (02629.HK)作为RNA检测领域的先锋企业,以其突破性的技术创新和独特的市场定位,在 资本市场 掀起层层波澜。这家源自新加坡的分子诊断公司,正凭借其在早期癌症筛查领域的领先优势,成为生物科技板块中最受瞩目的投资标的之一。自今年5月份登陆港交所以来,MIRXES-B便持续走强,特别是在9月份公司被正式纳入恒生 综合指数 及 港股通 ,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10